Insider Buying: Galectin Therapeutics CEO Acquires 4,000 Shares of Stock (GALT)
Galectin Therapeutics (NASDAQ:GALT) CEO Peter G. Traber purchased 4,000 shares of the stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $4.46 per share, for a total transaction of $17,840.00. Following the acquisition, the chief executive officer now directly owns 101,333 shares of the company’s stock, valued at approximately $451,945. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on GALT shares. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Shares of Galectin Therapeutics (NASDAQ:GALT) traded up 3.69% on Friday, hitting $4.78. 404,471 shares of the company’s stock traded hands. Galectin Therapeutics has a 1-year low of $4.28 and a 1-year high of $19.11. The stock’s 50-day moving average is $10.20 and its 200-day moving average is $12.76. The company’s market cap is $105.4 million.
Galectin Therapeutics (NASDAQ:GALT) last released its earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-1.03 EPS for the current fiscal year.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.